Lege Artis Medicinae

[Occurrence of cardiometabolic risk factors among shift workers]

JERMENDY György, NÁDASI Judit, HEGYI Ilona, VASAS István, HIDVÉGI Tibor

DECEMBER 21, 2011

Lege Artis Medicinae - 2011;21(12)

[INTRODUCTION - Shift workers have an impaired circadian rhythm, which might have an adverse effect on their health. In order to assess cardiometabolic risk in shift workers, a cross-sectional study was performed among active workers (aged 25-66 years, with a minimal shift working experience of 5 years). METHODS - In total 481 workers (121 men, 360 women) registered by the occupational health service were enrolled in our study. Most participants worked in the light industry (58.2%) or in public service (23.9%). Following questionnaire-based data recording, anthropometric measurements and physical examination were performed and fasting venous blood sample was taken for measuring laboratory parameters. Data from shift workers (n=234, 54 men and 180 women, age: 43.9±8.1 years) were compared with those of day workers (n=247, 67 men and 180 women, age: 42.8±8.5 years). RESULTS - Compared with day workers, shift workers had bigger weight (76.6±16.1 vs 73.9±17.6 kg; p<0.05), higher BMI index (27.5±5.3 vs 26.0±4.9 kg/m2; p<0.01) and systolic blood pressure (123±19 vs 119±16 mmHg, p<0.01), and higher prevalence rate of diabetes (4.3 vs 1.2 %; p<0.05) and cardiovascular diseases (3.8 vs 0.8 %; p<0.05). In addition, the proportion of participants who performed regular physical activity was lower (20.6 vs 38.7 %; p<0.001) and that of current smokers were higher (35.0 % vs 19.5 %; p<0.001) in shift workers than in day workers. In laboratory findings, only one difference has been found: HDL-cholesterol level was lower among women (shift workers versus workers: 1.56±0.32 vs 1.68±0.36 mmol/l; p<0.01). CONCLUSION - Long-term shift work (day-night) results in a less healthy lifestyle and worse cardiometabolic risk factors compared with day work. Thus, our study highlights the importance of measures for preventing cardiovascular diseases in shift workers.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Christmas in Medicine ]

KISS László

Lege Artis Medicinae

[Social Responsibilities of a Physician ]

SÓLYOM Antal, BÁLINT Géza

Lege Artis Medicinae

[A Tame Artist Among the ‘Wild”: The Life and Art of Rik Wouters]

NÉMETH István

Lege Artis Medicinae

[On the borderline]

KAPÓCS Gábor

Lege Artis Medicinae

[They are really saved]

FARSANG Csaba

All articles in the issue

Related contents

Lege Artis Medicinae

[Cardiovascular prevention 2021 – Guidelines of European Society of Cardiology 2021. General principles]

VÁLYI Péter, KÉKES Ede

[On 31 August 2021, the European Society of Cardiology published its guideline “Prevention of cardiovascular disease in clinical practice”. This guideline provides a comprehensive review about risk factors of atherosclerotic cardiovascular disease, their assessment, potential modifiers, treatment and prevention of the cardiovascular disease itself at societal and individual levels respectively. The previous guideline issued 2016, had to be updated due to the recent significant advances in risk prediction of cardiovascular disease on atherosclerotic background and due to the beneficial effects of treatment, emerging new drugs and therapeutic targets. The risk assessment system has undergone a major overhaul and now predicts the risk of fatal and non-fatal cardiovascular events together over a 10-year horizon and over a lifetime. In the new guideline, age plays a more important role in risk classification than before. The risk assessment and staged management of apparently healthy people or patients with established atherosclerotic cardiovascular disease, diabetes mellitus and other specific diseases or conditions are detailed. The positive impact of influencing risk factors, the years of life gained can recently be presented in a lifetime perspective, which will help to make an individually tailored decision on the extent of interventions, taking into account also the patient'’s preferences.]

Hypertension and nephrology

[Hypertension-infertility. Can be any connection between them?]

KAPOCSI Judit

[Summary – Considering the pathomechanism, the risk factors, as well as the environmental and toxic effects, some associated illnesses, unhealthy life-style habits in the background of hypertension and infertility, significant overlapping can be found. The question arises; does play any role the hypertension in the development of infertility? In this article the author review the connection between the hypertension and infertility. ]

Lege Artis Medicinae

[Cardiovascular prevention 2021 – Guidelines of European Society of Cardiology 2021. Cardiovascular prevention at individual level]

VÁLYI Péter, KÉKES Ede

[In August 2021, the European Society of Cardiology (ESC) published its practical guidelines for cardiovascular prevention. In Part 1 of our publication, we discussed cardiovascular risk factors, risk assessment, cardiovascular risk assessment in presumably healthy individuals of different ages, people with proven atherosclerotic cardiovascular disease, people with diabetes mellitus, and factors influencing risk. In Part 2, conditions that influence cardiovascular risk were detailed. In the current Part 3 of this publication, we review personalised cardiovascular prevention, non-pharmaceutical and pharmaceutical treatment of specific risk factors, emerging treatment options, and par­ticipation in cardiovascular rehabilita­tion and prevention programmes based on ESC guidelines.]

Lege Artis Medicinae

[Cardiovascular prevention 2021 – Guidelines of European Society of Cardiology 2021. Special considerations]

VÁLYI Péter, KÉKES Ede

[On 31 August 2021, the European Society of Cardiology published its guideline “Prevention of cardiovascular disease in clinical practice”. This guideline provides a comprehensive review about risk factors of atherosclerotic cardiovascular disease, their assessment, potential modifiers, treatment and prevention of the cardiovascular dis­ease itself at societal and individual levels respectively. The previous guideline issued 2016, had to be updated due to the recent significant advances in risk prediction of cardiovascular disease on atherosclerotic background and due to the beneficial effects of treatment, emerging new drugs and therapeutic targets. The risk assessment system has undergone a major overhaul and now predicts the risk of fatal and non-fatal cardiovascular events together over a 10-year horizon and over a lifetime. In the new guideline, age plays a more important role in risk classification than before. The risk assessment and staged management of apparently healthy people or patients with established atherosclerotic cardiovascular disease, diabetes mellitus and other specific diseases or conditions are detailed. The positive impact of influencing risk factors, the years of life gained can recently be presented in a lifetime perspective, which will help to make an individually tailored decision on the extent of interventions, while taking into account also the patient’s preferences.]

Hypertension and nephrology

[Cardiovascular prevention in hypertensive patients - use an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker?]

BARNA István

[The primary aim of cardiovascular prevention is to reach adequate blood pressure control. To prevent the development of target organ lesion it is essential to use long-acting, well tolerable drugs without significant side effects. Angiotensin-converting enzyme (ACE) inhibitors are popular and excellent preparations but their side effects reduce life long patient compliance. Angiotensin II receptor blockers (ARBs) are effective drugs having unique tolerability and a capability to reduce cardiovascular morbidity and mortality to the same extent as the ACE inhibitors. Especially high risk patients benefit from their combination with thiazide diuretics or with calcium channel blockers. Clinical trials proved that telmisartan can be safely given and well tolerable alone or in combination to high risk cardiovascular patients, in heart and renal, peripheral vascular and cerebrovascular diseases combined or not with diabetes.]